Toxicological and Mutagenicity Study of Some Marketable Insomnia Medications

ABSTRACT

Insomnia, a habitual yet vicious disorder characterized by depriving of sleep resulting in patients to consume medications for relieving their minds. Of these medications, a few may possess the aptitude to harm the biochemical receptors of the human body, resulting in mutagenicity, and the body may manifest acute toxicological symptoms. Execution of quantitative analysis by QSAR (quantitative structure-activity relationship) methods forms a reliable platform for interpreting the toxicological status of insomnia medicines. Further molecular docking software was utilized for determining the extent binding affinity of the molecules on the protein structures

References:

• [1] Solomon, F., White, C. C., Parron, D. L., & Mendelson, W. B. (1979). Sleeping pills, insomnia and medical practice. New England Journal of Medicine, 300(14), 803-808.
• [2] Kang, D. Y., Park, S., Rhee, C. W., Kim, Y. J., Choi, N. K., Lee, J., & Park, B. J. (2012). Zolpidem use and risk of fracture in elderly insomnia patients. Journal of Preventive Medicine and Public Health, 45(4), 219.
• [3] Kripke, D. F. (2000). Chronic hypnotic use: deadly risks, doubtful benefit. Sleep medicine reviews, 4(1), 5-20.
• [4] Lucire, Y., & Crotty, C. (2011). Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics and personalized medicine, 4, 65
• [5] Chung, K. F., & Lee, C. K. (2002). Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. General hospital psychiatry, 24(6), 430-435.
• [6] Akindele, M. O., Evans, J. I., & Oswald, I. (1970). Mono-amine oxidase inhibitors, sleep and mood. Electroencephalography and clinical neurophysiology, 29(1), 47-56.
• [7] Obal Jr, F., & Krueger, J. M. (2003). Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci, 8(1), d520-550.
• [8] Winkler, A., Auer, C., Doering, B. K., & Rief, W. (2014). Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS drugs, 28(9), 799-816.
• [9] Trumic, E., Pranjic, N., Begic, L., Becic, F., & Asceric, M. (2012). Idiosyncratic adverse reactions of most frequent drug combinations longterm use among hospitalized patients with polypharmacy. Medical Archives, 66(4), 243.
• Bernstein, S., & Leff, R. (1967). Toxic psychosis from sleeping medicines containing scopolamine. New England Journal of Medicine, 277(12), 638-639.
• CHU, A. G., GUNSOLLY, B. L., SUMMERS, R. W., ALEXANDER, B., MCCHESNEY, C., & Tanna, V. L. (1983). Trazodone and liver toxicity. Annals of Internal Medicine, 99(1), 128-129.
• Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., … & Will, Y. (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicological Sciences, 103(2), 335-345.
• Toner, L. C., Tsambiras, B. M., Catalano, G., Catalano, M. C., & Cooper, D. S. (2000). Central nervous system side effects associated with zolpidem treatment. Clinical neuropharmacology, 23(1), 54-58.
• Darke, S., Deady, M., & Duflou, J. (2012). Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001–2010. Journal of forensic sciences, 57(5), 1259-1262.
• Robison, R. L., Van Ryzin, R. J., Stoll, R. E., Jensen, R. D., & Bagdon, R. E. (1984). Chronic toxicity/carcinogenesis study of temazepam in mice and rats. Toxicological Sciences, 4(3part1), 394-405.
• Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., … & Wang, J. (2016). PubChem substance and compound databases. Nucleic acids research, 44(D1), D1202-D1213.
• Tomasulo, P. (2002). ChemIDplus-super source for chemical and drug information. Medical reference services quarterly, 21(1), 53-59.
• Valerio Jr, L. G. (2009). In silico toxicology for the pharmaceutical sciences. Toxicology and applied pharmacology, 241(3), 356-370.
• Martin, T. (2016). User’s guide for TEST (version 4.2)(Toxicity Estimation Software Tool): A program to estimate toxicity from molecular structure.
• Bank, P. D. (1971). Protein data bank. Nature New Biol, 233, 223.

Download all article in PDF

WSN 204 (2025) 185-197

ADVERTISEMENT